STOCK TITAN

Biogen Inc - BIIB STOCK NEWS

Welcome to our dedicated page for Biogen news (Ticker: BIIB), a resource for investors and traders seeking the latest updates and insights on Biogen stock.

Biogen Inc (BIIB) delivers pioneering therapies for neurological disorders through cutting-edge biotechnology research. This page aggregates all official announcements, regulatory developments, and strategic updates directly from the company and verified sources.

Investors and healthcare professionals will find timely updates on clinical trial results, FDA approvals, earnings reports, and research partnerships. Track Biogen's progress in Alzheimer's disease treatments, multiple sclerosis therapies, and rare condition solutions through curated press releases and analysis.

Our news hub simplifies monitoring Biogen's pipeline advancements and market position. Key content includes product launch details, executive leadership changes, collaboration announcements, and financial performance data. All information is organized chronologically for efficient research and decision-making.

Bookmark this page for streamlined access to Biogen's latest developments in neuroscience innovation. Verify publication dates and consult original SEC filings for complete context on all disclosed information.

Rhea-AI Summary

Biogen Inc. (Nasdaq: BIIB) released its 2023 Corporate Responsibility Report, highlighting progress in key areas such as access to medicines, workforce diversity, community impact, and environmental sustainability. The report showcases achievements like adding new medicines to the portfolio, expanding access to treatments, increasing workforce diversity, supporting local communities, and enhancing environmental initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
none
-
Rhea-AI Summary
Biogen receives a positive CHMP opinion for TOFIDENCE™, a biosimilar referencing ROACTEMRA®. The CHMP's positive opinion is based on robust analytical, non-clinical, and clinical data comparing TOFIDENCE™ to ROACTEMRA®. If granted marketing authorization by the EC, TOFIDENCE™ will be used to treat rheumatoid arthritis, juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19. Biogen's biosimilars portfolio in Europe may see an addition of TOFIDENCE™, offering cost-effective treatment options with a new mechanism of action. The recommendation signifies a step towards providing more patients with high-quality biologic medicines. The positive opinion was supported by analytical, non-clinical, and clinical data, confirming TOFIDENCE™ as a biosimilar to the reference product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
none
-
Rhea-AI Summary
Eisai and Biogen submit a sBLA for LEQEMBI maintenance dosing for Alzheimer's disease treatment. Fast Track designation sought for SC formulation. LEQEMBI aims to reduce protofibrils' impact on brain injury.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
none
Rhea-AI Summary
AbCellera (ABCL) partners with Biogen Inc. (BIIB) to discover antibodies for brain-targeted biotherapeutics in neuroscience. The collaboration aims to address the challenge of delivering biologics across the blood-brain barrier. AbCellera will receive upfront payment, milestone payments, and potential royalties on future product sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
none
-
Rhea-AI Summary
Biogen Inc. announced positive interim 6-month biomarker data from the open-label RESPOND study, showing reductions in neurofilament levels in most participants treated with SPINRAZA. The Phase 4 study focuses on infants and toddlers with spinal muscular atrophy (SMA) who have unmet clinical needs after Zolgensma treatment. The data indicate improvements in motor function and reductions in neurodegeneration, highlighting the potential benefits of SPINRAZA in maximizing patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
-
Rhea-AI Summary
Biogen Inc. to present new data on Alzheimer's disease portfolio at AD/PD™ 2024 conference, showcasing advancements in tau aggregation inhibition and disease progression understanding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
none
Rhea-AI Summary
Biogen receives positive opinion from CHMP for QALSODY® (tofersen) for the treatment of SOD1-ALS, marking a significant milestone in ALS treatment with potential to target genetic causes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
-
Rhea-AI Summary
Biogen's SKYCLARYS (omaveloxolone) receives European Commission approval for treating Friedreich’s ataxia, marking a significant advancement in rare disease treatment. The groundbreaking therapy demonstrated improved patient function in clinical trials, offering hope for patients with this debilitating condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.39%
Tags
none
-
Rhea-AI Summary
Aptar Digital Health, a part of AptarGroup, Inc., has entered into an enterprise agreement with Biogen Inc. to develop digital health solutions for neurological and rare diseases globally. The collaboration will cover several indications in neurology and immunology across 15 countries, focusing on providing advanced digital solutions for disease management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none
Rhea-AI Summary
Biogen Inc. announces plans to reprioritize resources in Alzheimer's disease, focusing on advancing LEQEMBI and developing new treatment modalities. The company will discontinue the development of ADUHELM and terminate the ENVISION clinical study, with no safety or efficacy concerns. Biogen will accelerate the development of potential new treatment modalities, including ASO targeting tau and an oral small molecule inhibitor of tau aggregation. The decision is part of a strategic review to prioritize the company's portfolio and will result in a one-time charge of approximately $60 million related to close out costs for the program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
none
Biogen Inc

Nasdaq:BIIB

BIIB Rankings

BIIB Stock Data

17.41B
145.56M
0.21%
94.46%
2.54%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE